Home
Join A Case
Contact
MoreThe investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. American Banker reported on May 29, 2023, that it had been given internal Comerica documents that showed its management recognizing compliance failures in its operations related to a Treasury Department program providing federal benefits on prepaid cards. Based on this news, shares of Comerica fell by 3.6% on May 30, 2023.
Archives: Cases
NextEra Energy, Inc.
According to the Complaint, the Company made false and misleading statements to the market. NextEra’s subsidiary, FPL, engaged in misconduct aimed at politicians and journalists that opposed it. The Company denied this misconduct despite the fact that the actions of its subsidiary put it at risk of legal and reputational damage. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about NextEra, investors suffered damages.
Luminar Technologies, Inc.
According to the Complaint, the Company made false and misleading statements to the market. Luminar improperly used an image of a competitor’s product to market its own products and capabilities. The Company was placed at risk of lawsuits and enforcement action based on its actions. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Luminar, investors suffered damages.
Freshpet, Inc.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Freshpet, Inc. (“Freshpet” or “the Company”) (NASDAQ: FRPT) for violations of the securities laws and potential breaches of fiduciary duty on the part of its directors and management.
Stratasys Ltd.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Stratasys Ltd. (“Stratasys” or “the Company”) (NASDAQ: SSYS) for potential breaches of fiduciary duty on the part of its directors and management.
Digital Turbine, Inc.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Digital Turbine, Inc. (“Digital Turbine” or “the Company”) (NASDAQ: APPS) for violations of the securities laws.
Cutera, Inc.
According to the Complaint, the Company made false and misleading statements to the market. Cutera overstated its potential for sustained revenue growth. The Company failed to disclose material conflicts of interest amongst its Board of Directors and senior executives. The Company failed to maintain effective controls over financial reporting. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Cutera, investors suffered damages.
Rain Oncology Inc.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Rain issued a press release on May 22, 2023, announcing topline results from its Phase 3 MANTRA trial of milademetan. The Company’s press release stated, “the trial, evaluating the efficacy, safety, and tolerability of milademetan in patients with dedifferentiated (DD) liposarcoma (LPS), did not meet its primary endpoint of progression free survival (PFS) by blinded independent central review compared to the standard of care, trabectedin” and stated that “[b]ased upon these topline data, Rain does not expect to pursue further development of milademetan in DD LPS.” Based on this news, shares of Rain fell by more than 88.7% on the same day.
Canopy Growth Corporation
According to the Complaint, the Company made false and misleading statements to the market. Canopy Growth failed to maintain effective controls over accounting and financial reporting. The Company improperly accounted for sales in its BioSteel business. As a result, the Company’s revenue was overstated. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Canopy Growth, investors suffered damages.
PTC Therapeutics, Inc.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or “the Company”) (NASDAQ: PTCT) for violations of the securities laws.